原发性硬化性胆管炎无创预后检测的系统综述
Mayo风险评分(MRS)研究最多,c-statistic为0.63-0.85;UK-PSC评分和PREsTo预测性能更优,瞬时弹性成像>11.1 kPa与生存和肝脏相关并发症相关。
要点
- MRS是研究最多的PSC预后评分,c-statistic为0.63-0.85
- UK-PSC评分预测临床结局优于MRS(c-statistic 0.81 vs 0.75)
- 瞬时弹性成像>11.1 kPa与生存和肝脏相关并发症相关
核心结论
- MRS是PSC临床结局研究最多的预后评分,但UK-PSC评分和PREsTo的检测性能更好。
- 尚需进一步研究比较MRS与UK-PSC评分、PREsTo或ELF与弹性成像或影像学评分的性能。
研究设计与样本
- 系统综述,检索1987年至2020年关于PSC血液检测、生化模型、弹性成像和影像评分与结局关联的研究。
主要发现
- 碱性磷酸酶正常化或下降(无论是否治疗)与无移植生存和肝胆癌风险降低相关,但各研究间碱性磷酸酶截断值不一致。
- MRS在18项研究中评估,临床结局的c-statistic为0.63至0.85。
- 一项研究显示UK-PSC评分预测临床结局优于MRS,c-statistic分别为0.81和0.75。
- 瞬时弹性成像评分大于11.1 kPa与生存和肝脏相关并发症相关。
- 基于特定MRI和MRCP特征的Anali评分与胆管癌和失代偿性肝硬化发生相关;有前景的模型包括ELF评分、ELF检测和PREsTo评分。
关键数值与推荐
- 碱性磷酸酶正常化或下降与无移植生存和肝胆癌风险降低相关,但截断值不一致。
- MRS临床结局c-statistic为0.63至0.85。
- UK-PSC评分与MRS预测临床结局的c-statistic分别为0.81和0.75。
- 瞬时弹性成像评分大于11.1 kPa与生存和肝脏相关并发症相关。
临床怎么用
- 可考虑使用MRS评估PSC患者临床结局风险,但需知晓UK-PSC评分和PREsTo预测性能可能更优。
- 瞬时弹性成像评分大于11.1 kPa提示生存和肝脏相关并发症风险,可辅助风险分层。
- 碱性磷酸酶正常化或下降可作为无移植生存和肝胆癌风险降低的参考指标,但截断值尚不统一。
局限性
- 各研究间碱性磷酸酶截断值不一致。
- 多数非无创检测研究未纳入本综述分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several prognostic tests for primary sclerosing cholangitis (PSC) have been developed, including biochemical models, elastography and magnetic resonance imaging scores. AIM: To conduct a systematic review of non-invasive prognostic tests for PSC. METHODS: A systematic review was conducted from 1987 to 2020 of blood tests, biochemical models, elastography and imaging scores associated with outcomes in PSC. RESULTS: Forty studies of prognostic tests that collectively included 16 094 subjects with PSC were reviewed, of which 26 studies of non-invasive tests including 13 759 subjects with PSC were included. Normalisation or reduction of alkaline phosphatase with or without therapy was associated with transplant-free survival and reduced risk of hepatobiliary cancers but cut-off values for alkaline phosphatase were not consistent among studies. The most studied prognostic biochemical model was the Mayo Risk Score (MRS) evaluated in 18 studies with a c-statistic from 0.63 to 0.85 for clinical outcomes. One study demonstrated that the UK-PSC score outperforms MRS for predicting clinical outcomes with a c-statistics of 0.81and 0.75 respectively. A transient elastography score greater than 11.1 kPa is associated with survival and liver-related complications. The Anali score, derived from specific MRI and MRCP features, is associated with the development of cholangiocarcinoma and decompensated cirrhosis. Promising prognostic models include the enhanced liver fibrosis (ELF) score, ELF test and PREsTo scores. CONCLUSION: MRS is the most studied prognostic score for clinical outcomes in PSC but the UK-PSC score and PREsTo have better test performance. Further studies comparing MRS to UK-PSC score, PREsTo or ELF with elastography or imaging-based scores are warranted.
引用
- Mazhar A, Russo MW. Systematic review: non-invasive prognostic tests for primary sclerosing cholangitis. Aliment Pharmacol Ther. 2021. PMID: 33608929. doi:10.1111/apt.16296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。